Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2). J of Skin [Internet]. 2017 Oct. 27 [cited 2025 May 18];1(3.1):s23. Available from: https://skin.dermsquared.com/skin/article/view/125